NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)

NEW YORK--(BUSINESS WIRE)-- NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to immediately suspend trading in the common stock of Timber Pharmaceuticals, Inc. (the “Company”) — ticker symbol TMBR — from NYSE American.

On November 21, 2023, the NYSE American announced that it was commencing proceedings to delist the Company. The Company had the right to request a review of this determination by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. On November 28, 2023, the Company confirmed that it will not exercise that right. Accordingly, the NYSE American will now suspend trading in the common stock and will file a delisting application with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231129559960/en/

Company Contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chairman and Chief Executive Officer
[email protected]

NYSE Contact:
NYSE Communications
[email protected]

Source: NYSE Regulation

You May Also Be Interested In

• UAE Opens 15th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million
• Next 100x Crypto: Pepeto Presale Keeps Filling as the Fed Writes New Stablecoin Rules and LINK, XRP Gain
• QFC-U.S. Chamber of Commerce Collaborate to Broaden Cross-Border Investment